Tina deVries
YOU?
Author Swipe
View article: Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study Open
Baclofen, a racemic γ-aminobutyric acid B receptor agonist, is commonly used for the management of multiple sclerosis–related spasticity but is associated with frequent dosing and poor tolerability. Arbaclofen, the active R-enantiomer of b…
View article: Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial Open
Baclofen, a racemic GABA-B (GABAB) receptor agonist, is commonly used for the management of multiple sclerosis-related spasticity but is associated with frequent dosing and poor tolerability. Arbaclofen, the active R-enantiomer of baclofen…
View article: Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies Open
BackgroundImmediate-release (IR) amantadine has been used for treatment of levodopa induced dyskinesia (LID). The immediate-release/extended-release (IR/ER) amantadine formulation OS320 (OSMOLEX ER®) contains an IR outer layer and ER core …
View article: Clinical Safety and Pharmacokinetics of FMX101 4% Topical Minocycline Foam in Pediatric Patients for the Treatment of Moderate-to-Severe Acne Vulgaris
Clinical Safety and Pharmacokinetics of FMX101 4% Topical Minocycline Foam in Pediatric Patients for the Treatment of Moderate-to-Severe Acne Vulgaris Open
not available.
View article: Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies Open
Osmotica Pharmaceutical US LLC.
View article: Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets Open
Renal impairment was associated with reduced amantadine clearance. Based on pharmacokinetic modeling and simulations, dose regimens were recommended for subjects with impaired renal function to provide systemic amantadine exposure similar …
View article: Pharmacokinetic Evaluation of Once-Daily Topical 4% Minocycline Foam in Adult and Pediatric Subjects with Moderate-to-Severe Acne in Two Phase 1 Studies
Pharmacokinetic Evaluation of Once-Daily Topical 4% Minocycline Foam in Adult and Pediatric Subjects with Moderate-to-Severe Acne in Two Phase 1 Studies Open
not available. Disclosures: Study s supported by Foamix Pharmaceuticals, Inc. Copyright SKIN 2018